VC
IMVT icon

Vivo Capital’s Immunovant IMVT Stock Holding History

Vivo Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-532,847
Closed -$5.63M – 62
2021
Q2 		$5.63M Hold
532,847
– – 0.24% 52
2021
Q1 		$8.55M Buy
532,847
+185,185
+53% +$4.88M 0.3% 48
2020
Q4 		$16.1M Sell
347,662
-694,798
-67% -$32.1M 0.72% 33
2020
Q3 		$36.7M Buy
1,042,460
+242,460
+30% +$7.29M 2.12% 9
2020
Q2 		$19.5M Buy
+800,000
New +$17.1M 1.4% 18

Other funds holding IMVT

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vivo Capital's IMVT Position: Q3 2021 in Review

Vivo Capital sold out of Immunovant (IMVT) in Q3 2021, closing a stake of 532,847 shares — an estimated $5.63M sold.

Vivo Capital first reported a position in IMVT in Q2 2020 and held it in 5 quarters. The position peaked at $36.7M in Q3 2020. 119 funds tracked by Wall St. Rank hold IMVT as of Q3 2021.

  • Vivo Capital reported no remaining Immunovant position as of Q3 2021 after selling out during the quarter.
  • Vivo Capital sold 532,847 Immunovant shares in Q3 2021, an estimated $5.63M.
  • Vivo Capital first reported a position in Immunovant in Q2 2020 and held it in 5 quarters.
  • Vivo Capital's Immunovant position peaked at $36.7M in Q3 2020.
  • 119 funds tracked by Wall St. Rank held Immunovant as of Q3 2021.

Based on Vivo Capital's 13F filing for Q3 2021, filed 15 Nov 2021.